Deal Announcements

IRX Gets $25 Million In First Financing Effort

Wednesday, June 04, 2008 5:59:00 AM PDT | VentureDeal Staff

New York, New York --  Biotechnology company IRX Therapeutics announced that it has received $25 million in its first institutional capital funding round.

IRX is developing drugs that stimulate the TH1-specific cellular immune response in human diseases, which is essential for the elimination of most viruses in tumors.

The company did not disclose participating investors.  It did say that the new funding will be used to continue to develop its cancer and viral disease product platform, which includes the IRX-2 (citoplurikin) lead cancer treatment candidate.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin

PCI - Level1